Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VENTRITEX PATENT CROSS-LICENSING AGREEMENTS WITH CPI, TELECTRONICS

This article was originally published in The Gray Sheet

Executive Summary

VENTRITEX PATENT CROSS-LICENSING AGREEMENTS WITH CPI, TELECTRONICS for implantable defibrillators will result in Ventritex recognizing a charge of about $19 mil. for the fourth quarter ended June 30, the firm says in a July 27 press release announcing the agreements. The charge includes one-time payments to Lilly subsidiary Cardiac Pacemakers, Inc. and Telectronics, "as well as other related settlement expenses." In addition to the one-time payments to both firms, Ventritex will pay royalties to CPI on sales of products incorporating the licensed patents. Ventritex markets the Cadence third-generation implantable pacemaker- cardioverter-defibrillator, which was launched in the spring ("The Gray Sheet" May 10, p. 3). The Cadence is the Sunnyvale, California firm's first commercially marketed product. Frank Fischer, president and CEO, said the two recent agreements will provide "expanded design freedom for future products." Specific terms of the agreements were not disclosed. The licensing agreements resolve a pending patent infringement case between Ventritex and Telectronics and threatened litigation with CPI. Ventritex and CPI have been involved in patent-related discussions for the last several months; according to CPI, the licensing agreement "settled all outstanding patent issues." In May 1992, Ventritex entered into a cross-licensing agreement with Medtronic covering patents for devices used to treat tachyarrhythmias ("The Gray Sheet" Sept. 14, 1992, p. 4). That agreement, like the one with CPI, includes royalty payments. As a result of the recent licensing agreements, Intermedics is the only remaining implantable defibrillator firm with which Ventritex has pending patent infringement litigation. Earlier this month, a U.S. District Judge for the Northern District of California dismissed an action filed by Ventritex "seeking a declaration that seven of Intermedics' patents were invalid or not infringed by Ventritex' Cadence" device, according to Intermedics. A motion to file a supplemental complaint was denied. Intermedics filed an amended complaint against Ventritex alleging infringement of nine patents in May ("The Gray Sheet" May 10, p. 3). The case is pending in the U.S. District Court for the Southern District of Texas in Galveston, Texas.

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel